Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Market Cap	49.24B
Revenue (ttm)	12.10B
Net Income (ttm)	3.80B
Shares Out	n/a
EPS (ttm)	33.78
PE Ratio	12.97
Forward PE	13.59
Dividend	2.38 (0.50%)
Ex-Dividend Date	Aug 18, 2025

Volume	n/a
Average Volume	46
Open	473.20
Previous Close	486.40
Day's Range	473.20 - 473.20
52-Week Range	420.00 - 1,047.00
Beta	n/a
RSI	42.89
Earnings Date	Nov 3, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RGO

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD